Puma Biotechnology (NASDAQ: PBYI) CEO sells shares via 10b5-1 plan

Rhea-AI Filing Summary

Puma Biotechnology President and CEO Alan H. Auerbach, who is also a director and 10% owner of the company, reported two open-market sales of Puma common stock. On January 6, 2026, he sold 16,938 shares at a price of $5.844 per share. On January 7, 2026, he sold an additional 18,012 shares at $5.879 per share.

After these transactions, Auerbach beneficially owned 7,145,951 shares of Puma common stock directly. The filing notes that these transactions were made under a Rule 10b5-1(c) trading plan adopted on December 17, 2020, which is a pre-arranged plan intended to allow insiders to sell shares according to preset instructions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AUERBACH ALAN H

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BLVD., SUITE 2150

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		16,938	D	$5.844	7,163,963	D
Common Stock	01/07/2026		S(1)		18,012	D	$5.879	7,145,951	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 12-17-2020

	/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Puma Biotechnology (PBYI) report for Alan H. Auerbach?

The report shows that Alan H. Auerbach, Puma Biotechnology's President, CEO, director and 10% owner, sold Puma common stock in two open-market transactions on January 6 and 7, 2026.

How many Puma Biotechnology (PBYI) shares did Alan H. Auerbach sell and at what prices?

Alan H. Auerbach sold 16,938 shares of Puma Biotechnology common stock at $5.844 per share on January 6, 2026, and 18,012 shares at $5.879 per share on January 7, 2026.

How many Puma Biotechnology (PBYI) shares does Alan H. Auerbach own after these sales?

Following the reported transactions, Alan H. Auerbach beneficially owned 7,145,951 shares of Puma Biotechnology common stock directly.

Were Alan H. Auerbach’s Puma Biotechnology (PBYI) share sales under a 10b5-1 plan?

Yes. The filing states that the transactions were made under a Rule 10b5-1(c) trading plan with an adoption date of December 17, 2020.

What is Alan H. Auerbach’s role at Puma Biotechnology (PBYI)?

Alan H. Auerbach is reported as a director, President and CEO, and a 10% owner of Puma Biotechnology.

Is this Puma Biotechnology (PBYI) insider filing for one reporting person or a group?

The document indicates that the Form 4 is filed by one reporting person, namely Alan H. Auerbach.